lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is activated by reduced local oxygen concentrations at the tumor site.

Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation The following represents disclosure information provided ...

exerts dual effects on the tumor microenvironment (TME), necessitating integration with systemic therapies like immune checkpoint inhibitors (ICIs). Yet, therapeutic resistance, hypoxia-induced ...